OUTLOOK THERAPEUTICS
Price & Volume
Stats
See more52W Range | $0.16-$3.39 |
Market Cap | $234.7M |
Shares Short | 16M |
Financials
See moreRevenue (12 Mos) | $333,141 |
Revenue Growth (YoY) | 658.3% |
Gross Profit (12 Mos) | -$1.2M |
Diluted EPS | -$1.13 |
News
See moreYahoo Finance • 25 days ago
Outlook Therapeutics Wins FDA Appeal For NAMD Therapy; Stock Up
Yahoo Finance • 2 months ago
Outlook Therapeutics Announces Closing of $5.0 Million Registered Direct Offering
Yahoo Finance • 2 months ago
Outlook Therapeutics Completes Federal Dispute Resolution (FDR) Meeting with FDA for ONS-5010/LYTENAVA™ (bevacizumab-vikg)
Yahoo Finance • 2 months ago
FDA Accepts Outlook Therapeutics' FDRR To Resolve ONS-5010/LYTENAVA Regulatory Issues; Stock Up
About
CEO | Mr. Robert Charles Jahr |
CFO | Mr. Lawrence A. Kenyon CPA |
Address | 111 S. Wood Avenue, Iselin, NJ, United States, 08830 |
Sector | Healthcare |
Industry | Biotechnology |
Full-Time Employees | 17 |